Sunshine September-quarter profit rises 82.4% to Rs.2.3bn

Daily Mirror and Lanka Business Online report that Sunshine Holdings PLC’s consolidated profit after tax for the quarter ended September 30, 2026, increased 82.4% year on year to Rs. 2.3 billion. EconomyNext gives a different measure: it reports Rs. 1.45 billion in net profit attributable to equity holders, up 80.3% from Rs. 804.6 million a year earlier, and basic earnings per share of Rs. 0.74 compared with Rs. 0.41.

EconomyNext reports that quarterly revenue rose 32% to Rs. 21.65 billion. It says gross profit increased 19.8% to Rs. 6.30 billion, while higher costs of sales reduced the gross margin to 29.1% from 32.1%. EconomyNext attributes margin pressure to pharmaceutical price reductions imposed by the National Medicines Regulatory Authority and the weaker rupee’s effect on imported healthcare products.

EconomyNext says the Consumer sector grew 68.3% to Rs. 8.39 billion, supported by the consolidation of spice exporter Joint Agri Products Ceylon and higher tea export orders. It reports tea export revenue rose 60.9%, branded tea revenue increased 5.6%, and Agribusiness revenue edged up 2.1% to Rs. 2.75 billion. Healthcare revenue rose 20.5% to Rs. 10.50 billion, with growth at Lina Manufacturing offsetting a decline in the agency business.

Lanka Business Online reports that for the six months ended September 30, 2026, group revenue rose 24.4% to Rs. 40.2 billion and profit after tax increased 44.3% to Rs. 3.7 billion. Healthcare accounted for 49% of revenue, Consumer 37% and Agribusiness 14%. The outlet says gross profit rose 11.7% to Rs. 11.5 billion, but the gross margin fell to 28.7% from 31.9%; EBIT increased 10.5% to Rs. 6.1 billion as its margin narrowed to 15.1% from 17.0%.

Lanka Business Online reports that higher net finance income and a lower effective tax rate supported first-half profitability. It also quotes Group CEO Shyam Sathasivam describing regulatory pricing and currency movements as continuing pressures, while pointing to investments in local pharmaceutical manufacturing, digital healthcare and export-oriented businesses. EconomyNext reports that Sunshine finalized a 50:50 joint venture with India’s Zydus Lifesciences to establish an oral solid dosage plant in the Horana Export Processing Zone, with an estimated investment of US$20 million.

Written automatically by AI from the outlets’ own reports, and not reviewed by an editor. It can be wrong — the original report is the authority.